New Data For Alder BioPharmaceuticals' Eptinezumab Shows Long-Term Reduction in Episodic Migraine

New Data For Alder BioPharmaceuticals' Eptinezumab Shows Long-Term Reduction in Episodic Migraine

Source: 
CP Wire
snippet: 

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), announced on 4/24/18 that new twelve-month data from its PROMISE 1 Phase 3 clinical trial in episodic migraine patients. The data demonstrated that patients experienced even further reductions in migraine following the third and fourth quarterly infusions at both dose levels (100mg and 300mg) of eptinezumab, Alder’s lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP).